里昂发布研究报告指，石药集团(01093.HK) 发盈警，料2024财年纯利按年跌26%至43亿元人民币，主要是由于带量采购(VBP)对主要产品美素(Duomeisu)和津优力(Jinyouli)的影响。然而，考虑到最近完成的项目和未来更多潜在对外授权项目所带来的可观合作收入，该行认为公司今年盈利状况或达到拐点。
该行认为，短期市场情绪受压，但当前股价呈吸引力的风险回报。该行表示，将集团去年、今年及明年盈利预测分别降22.8%、升27.8%及降4.4%，同时维持其目标价为12元，认为最坏时刻已过，今年盈利有望反弹，重申其评级为“跑赢大市”。(ca/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-26 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.